Hologic (HOLX) to Acquire Gynesonics

Hologic, Inc. (Nasdaq: HOLX), a global champion of women’s health, today announced that it has signed a definitive agreement to acquire Gynesonics, Inc. (Gynesonics®), a privately held medical device company focused on the development of minimally invasive solutions for women’s health for approximately $350 million, subject to working capital and other customary closing adjustments.

Gynesonics, which is based in Redwood City, California, develops and sells the Sonata® System, a technology intended for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids, including those associated with heavy menstrual bleeding. The Sonata System combines real-time intrauterine ultrasound guidance with targeted radiofrequency ablation in an incisionless procedure.

“Gynesonics’ Sonata System complements our offering and will give GYN surgeons across the globe an expanded range of options to treat women suffering from heavy periods and fibroids,” said Brandon Schnittker, Division President of Surgical Solutions at Hologic. “This acquisition furthers our commitment to providing women with minimally invasive treatment options. We are enthusiastic about the future as we work to expand access to and drive innovation for treatments that enhance women’s quality of life.”

Completion of the acquisition is subject to customary closing conditions, including receipt of required regulatory approvals.

About Hologic, Inc.

Hologic, Inc. is a global champion of women’s health, focused on developing innovative medical technologies that effectively detect, diagnose and treat health conditions and raise the standard of care around the world. For more information on Hologic, visit www.hologic.com.

About Gynesonics

Gynesonics pioneered and launched the Sonata System, the first FDA-cleared medical device for diagnostic intrauterine imaging and transcervical treatment of certain symptomatic uterine fibroids. The Sonata System is an incisionless solution, clinically proven to reduce fibroid symptoms. For more information, go to www.gynesonics.com.

You May Also Be Interested In

• Trifecta Gold closes $1.66M private placement for Yukon exploration
• Gold Resource shareholders approve merger with Goldgroup Mining
• Lockheed Martin frontrunner for $3.5B Ultra Maritime deal, sources say - FT